FDA's Rejection of MDMA-Assisted Therapy

The FDA's recent decision to reject MDMA-assisted therapy for treating PTSD has sparked significant controversy and concern among experts in the field. This decision was surprising given the strong evidence supporting the therapy's efficacy, described as potentially the most effective treatment for mental illness since the National Institute of Mental Health was established. Experts liken the situation to historical breakthroughs in medicine, highlighting the overwhelming double-blind, randomized, placebo-controlled trials that demonstrate MDMA's safety and effectiveness. Critics are questioning the motivations behind the FDA’s decision, raising the possibility that it was influenced by misinformation rather than scientific evidence.